'Mad Money' Uncover...
Health Care: Drugs
Durect Corporation (DRRX: NASDAQ)
$0.81 -0.08 | -9.09%
05/20/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.81 |
| 52 Week High | 1.85 |
| 52 Week Low | 0.61 |
| Avg. Daily Vol. (Mil) | 0.69 |
| Beta (3 year) | 1.23 |
| Share Related Items | |
| Mkt Cap (Mil) | 82.53 |
| Shares Out (Mil) | 101.89 |
| Float (Mil) | 97.64 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.10 |
| Current Ratio | 6.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.15 |
| Price/Book | 2.46 |
| Price/Cash Flow | -4.40 |
| Per Share Data | |
| Earnings | -0.22 |
| Sales | 0.16 |
| Book Value | 0.33 |
| Cash Flow | -0.18 |
| Business Summary | |
|---|---|
| DURECT Corporation is a specialty pharmaceutical company. It develops pharmaceutical products based on its proprietary drug delivery technology platforms. | |
| General Information | |
| 10260 Bubb Road
Cupertino, CA 95014 |
|
| www.durect.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 102 | |
| CEO: James E. Brown,D.V.M. | |
| Short Interest | |
| Current Month (Mil) | 0.25 |
| Previous Month (Mil) | 0.15 |
| Short Interest Ratio (Days) | 0.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -48.40 |
| Return on Investments | -59.00 |
| Profitability | |
| Gross Margin | 76.10 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with DRRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ProRobert Bruce
- Userdonellisor
- UserTrading
- Userbaustin002 Portfolio 1
- UserBarron's Research Reports 1...
Latest DRRX Headlines from TheStreet
- Durect Corporation Stock Downgraded (DRRX) 05.07.13 | 05:05 am
- 4 Stocks Under $5 Moving Higher 03.19.13 | 03:03 pm
- 4 Stocks Under $5 Making Big Moves 02.26.13 | 02:02 pm
- 5 Stocks Setting Up to Break Out 01.25.13 | 01:01 pm
- 8 Stocks Under $10 Making Big Moves 08.30.12 | 02:08 pm
- Durect Corporation Stock Upgraded (DRRX) 07.24.12 | 05:07 am
- Alkermes Needs to Build on Drug Delivery Success 06.18.12 | 07:06 am
- Business Highlights 06.24.11 | 06:06 pm
- Durect Stock Gaps Down On Today's Open (DRRX) 06.24.11 | 09:06 am
- Pfizer, Pain Therapeutics Drug Rejected by FDA 06.24.11 | 08:06 am
Press Releases for DRRX
- DURECT Announces Submission Of New Drug Application For POSIDUR⿢ (SABER®-Bupivacaine) - PR Newswire 04.16.13 | 07:04 am
- DURECT Corporation Invites You To Join Its Fourth Quarter 2012 Earnings Conference Call - PR Newswire 02.22.13 | 08:02 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 02.05.13 | 08:02 am
- DURECT Announces Positive Results From Reldayâ¿¢ Phase 1 Clinical Trial - PR Newswire 01.03.13 | 07:01 am
- DURECT Announces Pricing Of Public Offering Of Common Stock - PR Newswire 12.06.12 | 07:12 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 11.13.12 | 09:11 am
- DURECT Corporation Invites You To Join Its Third Quarter 2012 Earnings Conference Call - PR Newswire 10.30.12 | 04:10 pm
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 08.21.12 | 08:08 am
- DURECT Announces Intent To Submit NDA For POSIDUR⢠For Post-Operative Analgesia - PR Newswire 08.06.12 | 04:08 pm
- DURECT Corporation Invites You To Join Its Second Quarter 2012 Earnings Conference Call - PR Newswire 07.26.12 | 04:07 pm
Partner Headlines for DRRX
- A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships - Seeking Alpha 03.18.13 | 09:03 am
- Durect Offers Two Shots On Goal, Almost 100% Upside - Seeking Alpha 02.26.13 | 09:02 am
- 3 Best Biotech Stocks For This Week (Part V) - Seeking Alpha 10.08.12 | 09:10 am
- DRRX - Initiating Coverage of DURECT Corp. - Analyst Blog - NASDAQ 09.11.12 | 02:09 pm
- Benzinga's Microcap Movers for Friday July 20, 2012 - Benzinga 07.21.12 | 05:07 pm
- Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT - Benzinga 03.01.12 | 04:03 pm
- DURECT Announces Top-line Data from BESST; Did Not Reach Statistical Significance - Benzinga 01.05.12 | 04:01 pm
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
- Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX) - Benzinga 08.05.10 | 09:08 am
- FDA Clears Hospira's Generic Drug - Analyst Blog - Zacks 06.25.10 | 01:06 pm
